| Treatment of HCV infection by targeting microRNA HLA Janssen, HW Reesink, EJ Lawitz, S Zeuzem, M Rodriguez-Torres, ... New England Journal of Medicine 368 (18), 1685-1694, 2013 | 2559 | 2013 |
| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 2017 | 2017 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 1558 | 2016 |
| Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ... Journal of the National Cancer Institute 106 (9), dju244, 2014 | 895 | 2014 |
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, ... Journal of clinical oncology 27 (16), 2705-2711, 2009 | 388 | 2009 |
| Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0 AP Chen, A Setser, MJ Anadkat, J Cotliar, EA Olsen, BC Garden, ... Journal of the American Academy of Dermatology 67 (5), 1025-1039, 2012 | 376 | 2012 |
| Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer MC Pietanza, SN Waqar, LM Krug, A Dowlati, CL Hann, A Chiappori, ... Journal of Clinical Oncology 36 (23), 2386-2394, 2018 | 351 | 2018 |
| Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ... Journal of Clinical Oncology 38 (13), 1378-1388, 2020 | 328 | 2020 |
| Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, ... Journal of Clinical Oncology 33 (30), 3409-3415, 2015 | 326 | 2015 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, ... Cancer research 71 (17), 5626-5634, 2011 | 303 | 2011 |
| RECIST 1.1–Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group LH Schwartz, L Seymour, S Litière, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 138-145, 2016 | 296 | 2016 |
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary … RL Coleman, MW Sill, K Bell-McGuinn, C Aghajanian, HJ Gray, KS Tewari, ... Gynecologic oncology 137 (3), 386-391, 2015 | 268 | 2015 |
| Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer J Gulley, AP Chen, W Dahut, PM Arlen, A Bastian, SM Steinberg, K Tsang, ... The Prostate 53 (2), 109-117, 2002 | 266 | 2002 |
| Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain KW Staver, RB Brinsfield Journal of Soil and Water Conservation 53 (3), 230-240, 1998 | 259 | 1998 |
| Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study JF De Groot, KR Lamborn, SM Chang, MR Gilbert, TF Cloughesy, ... Journal of Clinical Oncology 29 (19), 2689-2695, 2011 | 250 | 2011 |
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, ... Clinical cancer research 18 (6), 1726-1734, 2012 | 231 | 2012 |
| Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) KT Flaherty, RJ Gray, AP Chen, S Li, LM McShane, D Patton, SR Hamilton, ... Journal of Clinical Oncology 38 (33), 3883-3894, 2020 | 211 | 2020 |
| Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H AKS Salama, S Li, ER Macrae, JI Park, EP Mitchell, JA Zwiebel, HX Chen, ... Journal of Clinical Oncology 38 (33), 3895-3904, 2020 | 203 | 2020 |
| PARP inhibitors: its role in treatment of cancer A Chen Chinese journal of cancer 30 (7), 463, 2011 | 203 | 2011 |
| A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group ME Lacouture, ML Maitland, S Segaert, A Setser, R Baran, LP Fox, ... Supportive Care in Cancer 18, 509-522, 2010 | 203 | 2010 |
Martin GutierrezUNIVERSIDAD UNADM在 NUBE.UNADMEXICO.MX 的电子邮件经过验证
